Conrado Ordonez, MD
Internal Medicine · Rosenberg, TXNPI 1124225453
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 24.5% of the total. Reporting peaked in 2020 at $652 and has fallen 81.0% since, to $124 in 2025.
Across 137 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$612
- Lilly USA, LLC$601
- AstraZeneca$362
- Amgen$272
- AbbVie$124
- Sanofi-aventis U.S. LLC$110
- plus $415 from 7 others
What the payments were for
- Food & beverage$2,495100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $612 |
| Lilly USA, LLC | 31 | $601 |
| AstraZeneca | 21 | $362 |
| Amgen | 13 | $272 |
| AbbVie(2 entities) | 7 | $124 |
| Sanofi-aventis U.S. LLC | 6 | $110 |
| Boehringer Ingelheim | 5 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $75 |
| Merck | 5 | $72 |
| Exact Sciences | 4 | $59 |
| Abbott | 3 | $56 |
| GSK | 3 | $53 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
How this compares
$2,495 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 34 | $46,140 |
| JanuviaSitagliptin Phosphate | 37 | $44,690 |
| OzempicSemaglutide | 21 | $42,557 |
| TrulicityDulaglutide | 22 | $40,955 |
| FarxigaDapagliflozin Propanediol | 26 | $33,629 |
| TradjentaLinagliptin | 17 | $21,263 |
| LinzessLinaclotide | 16 | $18,643 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $13,363 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $12,236 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $9,076 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $8,938 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $5,016 |
| Alcohol PadsAlcohol Antiseptic Pads | 21 | $2,112 |
| Atorvastatin Calcium | 254 | $2,006 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $82 | $67,40351 claims |
| MerckJanuvia | $72 | $44,69037 claims |
| Novo NordiskOzempic | $612 | $42,55721 claims |
| Lilly USA, LLCTrulicity | $601 | $40,95522 claims |
| AstraZenecaFarxiga | $362 | $33,62926 claims |
| AbbVieLinzess | $124 | $18,64316 claims |
| GSKTrelegy Ellipta | $53 | $12,23616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Rosenberg
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.